In 2014, the IMWG has added SLiM criteria (bone marrow plasmacytosis ≥ 60%, FLC i/u ≥100 along with the iFLC ≥ 100 mg/L, > 1 focal lesion on MRI) to the CRAB criteria (calcium elevation, renal insufficiency, anemia), as Myeloma Defining Events.
The iFLCr threshold (100) was defined because it was the cut-off associated with a 79% risk of progression to MM (Multiple Myeloma) or AL (AL amyloidosis) within 24 months, and with a specificity of 97% (Larsen JT et al, Leukemia, 2013).
In addition to this 100 ratio, the IMWG has then introduced the 20-20-20 system for assessing the Smoldering Multiple Myeloma (SMM) to MM progression. In that system, a patient with SMM receives 1 risk point for each of the following (M-spike>20 g/L, iFLCr>20 and BMPC>20%). This score is notably used for trial stratification and eligibility.
This publication indicates that the FLC cut-points can be used with Sebia ELISA FLC tests and allow for comparability within the field, to ensure an appropriate patient management.
Test associated with this resource
Related instrument
Discover more resources on Multiple Myeloma
Software abrangente de análise e interpretação de dados para ensaios da Sebia em instrumentos de eletroforese.
Esta seção contém informações destinadas à ampla divulgação e, portanto, pode conter detalhes sobre produtos ou informações que não estejam disponíveis ou não sejam válidas em seu país. Entre em contato com o representante local da Sebia. Informações destinadas a profissionais de saúde. Leia atentamente as instruções contidas nas bulas dos reagentes e nos manuais dos instrumentos.